Lisanti Capital Growth LLC Sells 10,140 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Lisanti Capital Growth LLC lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 73.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,645 shares of the company’s stock after selling 10,140 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Medpace were worth $1,117,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of MEDP. SG Americas Securities LLC increased its position in shares of Medpace by 353.2% during the third quarter. SG Americas Securities LLC now owns 2,515 shares of the company’s stock worth $609,000 after acquiring an additional 1,960 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Medpace by 20.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 2,765 shares of the company’s stock valued at $669,000 after purchasing an additional 465 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Medpace by 13.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,755 shares of the company’s stock valued at $909,000 after purchasing an additional 440 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Medpace by 2.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,749 shares of the company’s stock worth $1,634,000 after buying an additional 163 shares during the period. Finally, Advisor Partners II LLC grew its holdings in shares of Medpace by 84.9% during the third quarter. Advisor Partners II LLC now owns 1,801 shares of the company’s stock worth $436,000 after buying an additional 827 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent research reports. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and upped their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their target price for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. Finally, Robert W. Baird raised their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Medpace presently has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Medpace Stock Performance

MEDP traded up $1.36 during trading hours on Tuesday, reaching $402.10. The company’s stock had a trading volume of 228,959 shares, compared to its average volume of 248,911. The company’s 50-day moving average is $398.03 and its 200-day moving average is $332.98. Medpace Holdings, Inc. has a 52 week low of $197.39 and a 52 week high of $421.00. The firm has a market cap of $12.46 billion, a PE ratio of 41.27, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same period in the prior year, the firm earned $2.27 earnings per share. The company’s revenue was up 17.7% on a year-over-year basis. Equities analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold 204,442 shares of company stock worth $82,702,867 in the last 90 days. Company insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.